ABBV•benzinga•
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)
Summary
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga